Revive Therapeutics Partners With University of Wisconsin-Madison For Psilocybin-Based Research

Revive Therapeutics (CSE: RVV) announced this morning that it has entered into a sponsored research partnership agreement with that of the University of Wisconsin-Madison. The partnership arrangement will see the University of Wisconsin-Madison work with the company to evaluate novel formulations and drug delivery tech focused on psilocybin-based pharmaceuticals.

The program will be conducted at the Reed Research Group, led by Dr Jess D Reed who is the Professor of Animal Sciences at the university. The research agreement with the University and Revive will see the evaluation of psilocybin-based formulations and the patented Tannin-Chitosan composite drug delivery tech for psilocybin. Revive has an exclusive licenses with the Wisconsin Alumni Research Foundation for this technology.

The tech behind the drug delivery method is focused on delivering both synthetic and natural extracts of psilocybin in a number of potential mediums. Potential methods include topical gels, creams or ointments, oral dosages, foams, and oral or transdermal patches. The method is a natural, non-toxic, biodegradable and biocompatible composite. The tech has rapid onset capabilities and may allow for the combining of multiple extracts from mushrooms in a single formulation.

"We are excited to partner with the University of Wisconsin-Madison and leverage our intellectual property of psilocybin-based formulations and our drug delivery technology to advance novel psilocybin-based pharmaceuticals for certain medical needs. We have established a sound foundation to allow us to efficiently develop unique psychedelic-based pharmaceuticals with the objective to investigate our drug products in clinical trials in the U.S."  - Michael Frank, CEO

In addition to the tech having a composite that is derived from a plant group having a number of antibacterial and antifungal properties, it offers licensed pharma firms new product opportunities for various medical disorders.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Revive Therapeutics last traded at $0.14 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

  1. This doesn’t look any more real or any more fake than the rest of the shroom deals. Not sure how anyone can assess the commercial viability of these.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Goliath Extends Golden Gate Lode 130 Metres With 13.45 g/t Gold Equivalent Over 4.85 Metres

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Related News

Is Vladimir Putin Getting Ready to Flee Russia?

Russian President Vladimir Putin may be on the brink of fleeing the country and going...

Thursday, February 9, 2023, 04:32:00 PM

$75 Silver Now More Likely Than $6,000 Gold? | Michael Williams – Aftermath Silver

Executive Chairman Michael Williams of Aftermath Silver Ltd. (TSXV: AAG) provides a comprehensive analysis of...

Sunday, May 25, 2025, 11:20:00 AM

Reed Hastings To Exit Netflix Board After 30 Years, Marking End of an Era

Reed Hastings, co-founder of Netflix (NASDAQ: NFLX), is stepping down from the company’s board of...

Thursday, April 16, 2026, 04:43:41 PM

Tesla Halts Shanghai Plant Production Due to Covid-19 Restrictions

Tesla (NASDAQ: TSLA) has reportedly decided to halt production at its Shanghai plant for several...

Monday, March 28, 2022, 05:34:00 PM

Bulk Snacks to Bullion: Costco Rakes in Millions Selling Gold Bars and Silver Coins

Costco (NASDAQ: COST) is striking gold with its latest venture into precious metals. According to...

Wednesday, April 10, 2024, 12:47:32 PM